key: cord-0815380-8xt8sdpq
authors: Tada, Takuya; Zhou, Hao; Dcosta, Belinda M.; Samanovic, Marie I.; Mulligan, Mark J.; Landau, Nathaniel R.
title: Partial Resistance of SARS-CoV-2 Delta Variants to Vaccine-elicited Antibodies and Convalescent sera
date: 2021-10-24
journal: iScience
DOI: 10.1016/j.isci.2021.103341
sha: c2af3455a765effb2e15637fae06276c37124de2
doc_id: 815380
cord_uid: 8xt8sdpq

Highly transmissible SARS-CoV-2 variants identified in India and designated B.1.617, Kappa (B.1.617.1), Delta (B.1.617.2), B.1.618 and B.1.36.29, contain spike mutations L452R, T478K, E484K, E484Q and N440K located within the spike receptor binding domain and thus could contribute to increased transmissibility and potentially allow re-infection or cause resistance to vaccine-elicited antibody. To address these issues, we used lentiviruses pseudotyped by variant spikes to measure their neutralization by convalescent sera, vaccine-elicited and Regeneron therapeutic antibodies and ACE2 affinity. Convalescent sera and vaccine-elicited antibodies neutralized viruses with Delta spike with 2-5-fold decrease in titer in different donors. Regeneron antibody cocktail neutralized virus with the Delta spike with a 2.6-fold decrease in titer. Neutralization resistance to serum antibodies and monoclonal antibodies was mediated by L452R mutation. These relatively modest decreases in antibody neutralization titer for viruses with variant spike proteins suggest that current vaccines will remain protective against the family of Delta variants.

Despite efforts to contain the severe acute respiratory syndrome coronavirus-2 (SARS-42

CoV-2) the virus has continued to spread throughout the world's population, generating 43 novel variants with mutations selected for immunoevasion and increased transmissibility. 44

The variants contain point mutations and deletions in the spike protein driven by selective 45 pressure for increased affinity for its receptor, ACE2, and escape from neutralizing To determine the resistance of the variants to neutralization by vaccine-elicited 117 antibodies, we tested sera from individuals vaccinated with Pfizer BNT162b2 and 118

Moderna mRNA-1273 vaccines for neutralization of the variant spike pseudotyped viruses. 119

The results showed a similar pattern of resistance to neutralization as for the 120 convalescent sera except that overall antibody titers were about 5-fold higher (Figures. 121 Monoclonal antibody therapy for COVID-19 has been shown to reduce disease symptoms 130 and hospitalization (Weinreich et al., 2021 We found no apparent synergy and optimal neutralization at a ratio of 1:1 ( Figure S2G) . To determine whether the increased transmissibility of the variants could be caused by 150 increased affinity for ACE2, we measured the relative ACE2 affinities of virion avidity 151 using an assay we have previously reported, in which pseudotyped viruses were 152 incubated with soluble ACE2 and then tested for infectivity on ACE2. The experiment was done twice with similar results. 300

Further information and requests for resources and reagents should be directed to and 

The effect of the D614G substitution on the 413 structure of the spike glycoprotein of SARS-CoV-2

Serum Neutralizing Activity of mRNA-416 1273 against SARS-CoV-2 Variants. bioRxiv

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

SARS -CoV-2 T-cell immunity 422 to variants of concern following vaccination. bioRxiv

The basis of a more contagious 501Y.V1 variant of SARS

BNT162b2-elicited neutralization of B.1.617 and other SARS

CoV-2 variants

SARS-CoV-2 spike L452R variant evades 441 cellular immunity and increases infectivity

Antibody isotype 444 diversity against SARS-CoV-2 is associated with differential serum neutralization 445 capacities

Reduced sensitivity of 454 infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from 455 convalescent and vaccinated individuals. bioRxiv

COVID-19 vaccine BNT162b1 elicits 458 human antibody and TH1 T cell responses

Deep Mutational Scanning of

SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2

Convalescent-Phase Sera and

CoV-2 Variant Spikes

Emergence and rapid spread

Neutralising antibody activity against SARS-CoV

1.617.2 and B.1.351 by BNT162b2 vaccination

Antibody resistance of SARS-CoV-2 variants B.1.351 and 480 B.1.1.7. Nature

REGN-COV2, a Neutralizing Antibody Cocktail, in 483 Outpatients with Covid-19

CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Serum Neutralizing Activity 490 Elicited by mRNA-1273 Vaccine

Neutralization of SARS-CoV-2 spike 69/70 deletion